(1S,4R,6S,14S,18R)-14-(((tert-butoxy)carbonyl)amino)-2,15-dioxo-18-((((2-trimethylsilanyl)ethoxy)carbonyl)amino)-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid ethyl ester | 866490-19-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,4R,6S,14S,18R)-14-(((tert-butoxy)carbonyl)amino)-2,15-dioxo-18-((((2-trimethylsilanyl)ethoxy)carbonyl)amino)-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid ethyl ester
• 英文别名: (1S,4R,6S,14S,18R)-14-(((tert-butoxy)carbonyl)amino)-2,15-dioxo-18-((((2-trimethylsilanyl)ethoxy)carbonyl)amino)-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid ethyl ester
• CAS: 866490-19-9
• 化学式: C₃₁H₅₂N₄O₈Si
• 分子量: 636.861
• InChiKey: IJBUKFGVMNASML-IAOYSVILSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.87
• 重原子数：
  44.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  152.37
• 氢给体数：
  3.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (1S,4R,6S,14S,18R)-14-(((tert-butoxy)carbonyl)amino)-2,15-dioxo-18-((((2-trimethylsilanyl)ethoxy)carbonyl)amino)-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid ethyl ester 在 四丁基氟化铵 、 水 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 3.0h， 生成 (1S,4R,6S,14S,18R)-{4-((cyclopropanesulfonyl)aminocarbonyl)-18-[(3,4-dihydro-1H-isoquinoline-2-carbonyl)amino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl}carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

  摘要：

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.

  DOI：

  10.1021/jm400164c
• 作为产物：
  描述：

  (1R,2S)-REL-1-[[(1,1-二甲基乙氧基)羰基]氨基]-2-乙烯基-环丙羧酸乙酯 在 盐酸 、 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 36.0h， 生成 (1S,4R,6S,14S,18R)-14-(((tert-butoxy)carbonyl)amino)-2,15-dioxo-18-((((2-trimethylsilanyl)ethoxy)carbonyl)amino)-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxylic acid ethyl ester
  参考文献：
  名称：

  Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

  摘要：

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.

  DOI：

  10.1021/jm400164c